Sign In
Buy HYPMY
$4.22
-0.0796 (-1.85%)
At Close: Jun 03, 2026
Hypermarcas (OTCMKTS:HYPMY) Sees Large Increase in Short Interest
03:28am, Sunday, 12'th Apr 2026
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw a large increase in short interest in March. As of March 31st, there was short interest totaling 3,024 shares, an increase of 18,800.0% from the March
Hypermarcas (OTCMKTS:HYPMY) Short Interest Update
04:05am, Thursday, 12'th Feb 2026
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 50,686 shares, a growth of 9,217
Hypermarcas (OTCMKTS:HYPMY) Short Interest Update
04:01am, Thursday, 12'th Feb 2026
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 50,686 shares, a growth of 9,217
Hypermarcas (OTCMKTS:HYPMY) Shares Gap Up – Here’s What Happened
03:16am, Friday, 02'nd Jan 2026
Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price gapped up before the market opened on Wednesday. The stock had previously closed at $4.00, but opened at $4.13. Hypermarcas shares last trad
Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript
03:36pm, Wednesday, 29'th Oct 2025
Hypera S.A. (OTCPK:HYPMY) Q3 2025 Earnings Call October 29, 2025 10:00 AM EDT Company Participants Breno Pires de Oliveira - Chief Executive Officer Ramon Frutuoso Silva - CFO & Investor Relation Offi
Brazil's Hypera announces new majority stakeholder group
05:59pm, Monday, 07'th Jul 2025
Brazilian drugmaker Hypera said on Monday that shareholders executed an agreement by which a new control group now holds 53% of share capital.
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
12:27pm, Friday, 21'st Mar 2025
Hypera S.A. (OTCPK:HYPMY) Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Breno Toledo Pires de Oliveira - Chief Executive Officer Adalmario Ghovatto Satheler do Couto
Hypera: Short-Term Pain For Long-Term Gain
05:00am, Tuesday, 26'th Nov 2024
Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have caus
Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio
09:40pm, Thursday, 29'th Oct 2020
In Reais, I believe there is a 30% upside on Hypera S.A. due to improving margins as the company increases its operation by acquiring other brands and internal development. 75% of the Sell-Side Analys
